文献速递青光眼角膜与眼表疾病

溴莫尼定被鉴定为眼内OCT2和MATE1转运体的新底物

Identification of Brimonidine as a Novel Substrate of Organic Cation Transporters OCT2 and MATE1 Expressed in Human Eye.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

本研究探讨溴莫尼定是否由有机阳离子转运体OCT1、OCT2、OCT3及MATE1、MATE2K转运,并定位相关转运体在眼前段结构中的表达。结果显示溴莫尼定经OCT2和MATE1转运,且二者表达于角膜、结膜和睫状体,提示其可能影响溴莫尼定的眼内摄取及个体间差异。

要点

  • 溴莫尼定是OCT2和MATE1的底物,而非OCT1、OCT3或MATE2K的底物。
  • OCT2和MATE1表达于人眼的角膜、结膜和睫状体。
  • OCT2和MATE1可能影响溴莫尼定的眼内浓度及药效个体差异。

核心结论

  • 溴莫尼定由OCT2和MATE1转运,OCT2和MATE1可能参与溴莫尼定进入人眼的过程,并可能导致溴莫尼定浓度和效应的个体间差异。

研究设计与样本

  • 使用稳定表达OCT1、OCT2、OCT3、MATE1和MATE2K的HEK293细胞进行摄取实验,并用质谱法分析细胞内溴莫尼定蓄积。
  • 采用免疫组织化学方法在青光眼人眼的眼前段结构中定位相关转运体。

主要发现

  • 溴莫尼定被OCT2和MATE1转运,但不被OCT1、OCT3或MATE2K转运,且摄取具有时间和浓度依赖性。
  • OCT2和MATE1均表达于角膜、结膜和睫状体。

临床怎么用

  • 溴莫尼定作为OCT2和MATE1底物,提示这些转运体可能影响其眼内递送和疗效,临床需关注个体间差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Brimonidine, a selective α2-adrenergic agonist, is widely used in topical therapy for ocular hypertension or primary open-angle glaucoma. However, effective delivery is hindered by multiple ocular surface barriers. Because brimonidine is a cationic drug, we hypothesized that organic cation transporters (OCTs) and multidrug and toxin extrusion proteins (MATEs) are involved in brimonidine uptake in the human eye. This study aimed to determine if brimonidine is transported by OCT1, OCT2, OCT3, MATE1, and MATE2K and if the identified transporters are localized in anterior eye structures. METHODS: Uptake studies were performed using HEK293 cells stably expressing OCT1, OCT2, OCT3, MATE1, and MATE2K. Intracellular brimonidine accumulation was analyzed by mass spectrometry. Immunohistochemistry of glaucomatous human eyes was used to localize relevant transporters in anterior ocular structures. RESULTS: Brimonidine was transported by OCT2 and MATE1 but not by OCT1, OCT3, or MATE2K. Uptake was time- and concentration-dependent. Both OCT2 and MATE1 were expressed in the cornea, the conjunctiva, and the ciliary body. CONCLUSIONS: These results imply that OCT2 and MATE1 may play a role in brimonidine uptake into the human eye and may contribute to the interindividual variability of brimonidine concentrations and effects.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Kölz C, Neul C, Hofmann U, et al. Identification of Brimonidine as a Novel Substrate of Organic Cation Transporters OCT2 and MATE1 Expressed in Human Eye. Invest Ophthalmol Vis Sci. 2026. PMID: 41925694. doi:10.1167/iovs.67.4.4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。